Zai Lab

Zai Lab company information, Employees & Contact Information

Explore related pages

Related company profiles:

Zai Lab is an innovative, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing transformative products that address medical conditions with significant unmet patient needs in the areas of oncology, autoimmune disorders, infectious diseases and neurological disorders. Our goal is to leverage our capabilities and resources to reach one million patients by 2030, positively impacting human health worldwide.

Company Details

Employees
533
Founded
-
Address
4560 Jinke Road, Jinchuang Plaza,building 1,4/f & Building 3
Phone
+86 21 6163 2588
Email
in****@****ory.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Zhangjiang Hi-tech Park, Pudong, Shanghai
Looking for a particular Zai Lab employee's phone or email?

Zai Lab Questions

News

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - Business Wire

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 Business Wire

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - Yahoo Finance

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer Yahoo Finance

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 Business Wire

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - The AI Journal

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference The AI Journal

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong - Yahoo Finance

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong Yahoo Finance

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for - GlobeNewswire

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for GlobeNewswire

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Yahoo Finance

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 Yahoo Finance

Top Zai Lab Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant